GlassScriptPhysician profile
James Kirk Zimmer
NPI 1306878772
$2,782.41
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,319 · 2020: $116 · 2021: $90.07 · 2022: $356 · 2023: $464 · 2024: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $636.78 | 2019-2024 | Breztri, Airsupra |
| Pfizer INC. | $354.98 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $254.25 | 2019 | |
| Abbvie INC. | $229.41 | 2019-2024 | Ubrelvy |
| Amgen INC. | $171.78 | 2019-2023 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $146.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $134.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.36 | 2019-2022 | |
| Lilly USA, LLC | $86.96 | 2019-2024 | Mounjaro |
| Exact Sciences Corporation | $84.40 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $73.49 | 2019-2024 | Arexvy |
| Mylan Specialty L.P. | $45.79 | 2019 | |
| Amag Pharmaceuticals, INC. | $43.17 | 2019 | |
| Abbott Laboratories | $43.14 | 2022-2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $41.51 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $41.32 | 2019-2022 | |
| Philips North America LLC | $34.01 | 2019 | |
| Xeris Pharmaceuticals, INC. | $30.94 | 2022-2023 | Gvoke Hypopen |
| Allergan, INC. | $30.44 | 2019-2020 | |
| Radius Health, INC. | $28.12 | 2024 | Tymlos |
| Covis Pharma Gmbh | $25.12 | 2019 | |
| Alfasigma USA, INC. | $24.25 | 2022 | |
| Lupin INC. | $22.42 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $21.60 | 2021 | |
| Merck Sharp & Dohme LLC | $19.38 | 2020 | |
| Bausch Health US, LLC | $19.33 | 2022 | |
| Dexcom, INC. | $16.48 | 2022 | |
| Genentech USA, INC. | $15.36 | 2019 | |
| Biocryst US Sales Co., LLC | $13.50 | 2024 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Zimmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.